NCT07079644View on ClinicalTrials.gov

Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

CompletedOBSERVATIONAL
Enrollment

678

Participants

Timeline

Start Date

November 29, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Advanced Melanoma
Interventions
BIOLOGICAL

Nivolumab + Relatlimab

As per product label

BIOLOGICAL

Nivolumab + Ipilimumab

As per product label

BIOLOGICAL

Immunotherapy monotherapy

As per product label

DRUG

BRAF/MEK inhibitors

As per product label

Trial Locations (1)

08540-4715

Bristol Myers Squibb, Princeton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT07079644 - Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database | Biotech Hunter | Biotech Hunter